JUNS Jupiter Neurosciences, Inc.
$2.56▼ -3.03%
Healthcare
Other
Volume 2.7K
Avg Volume (10D) 18.6K
Key Metrics & Fundamentals
Market Cap
$3.38M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.25 - 127.50
% vs 50 MA
-20.63%
% vs 200 MA
-87.76%
RSI-14
41.2
MACD Histogram
+0.0600
Beta (1Y vs SPY)
1.50
Free Cash Flow
-$2.29M
Gross Rev
$24,245
Gross Profit
$21,064
EBITDA
-$2.18M
COGS
$3,181
Operating Exp
$2.76M
Operating Income
-$2.74M
EBIT
-$2.74M
Pretax Income
-$2.27M
Net Income
-$2.27M
EPS (Diluted)
-4.08
Price & Volume History
Loading chart…
Recent News
Sector Update: Healthcare Stocks Mixed Late Afternoon
MT Newswires · Oct 6, 2026 3:51 PM ET
Sector Update: Healthcare Stocks Mixed Tuesday Afternoon
MT Newswires · Oct 6, 2026 1:46 PM ET
Jupiter Neurosciences Explores Strategic Options
MT Newswires · Oct 6, 2026 11:55 AM ET
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
GlobeNewswire · Oct 6, 2026 11:15 AM ET
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Market Exclusive · Aug 31, 2026 10:12 AM ET
Top Premarket Decliners
MT Newswires · Aug 25, 2026 7:34 AM ET
Sector Update: Healthcare Stocks Advance Late Afternoon
MT Newswires · Aug 21, 2026 3:48 PM ET
Jupiter Neurosciences Prices $2.0 Million Direct Offering
MT Newswires · Aug 21, 2026 12:52 PM ET
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
GlobeNewswire · Aug 21, 2026 12:20 PM ET
Real Parkinson’s Disease Hope from Jupiter Neurosciences
Exec Edge · Aug 19, 2026 12:32 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See JUNS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.